Johnson Matthey acquired the Pharmorphix® solid form research business from Sigma-Aldrich on 1st October 2015. The acquisition brings world-leading material science capabilities to Johnson Matthey's expanding European API and clinical supply services
Pharmorphix is an established provider of solid form services, including polymorph studies, salt selection, co-crystallization, chiral separations and process scale up that are critical to successful drug discovery and development.
The acquisition adds to our advanced catalysis and complex chemistry capabilities
This expertise also has valuable applications for process control, and can enable innovators or generics customers to find new forms for novel or existing pharmaceuticals.
"Pharmorphix serves an important niche area that complements our custom pharma solutions, API life cycle management offerings and existing US-based solid state science capabilities," said John Fowler, Division Director, Johnson Matthey Fine Chemicals. "The acquisition adds further differentiating technologies to our advanced catalysis and complex chemistry capabilities, building on the expertise that our customers rely on to enable successful drug development and commercialisation."
The Pharmorphix facilities and staff are located at the Cambridge Science Park, UK, where they will be fully integrated into Johnson Matthey's expanding Cambridge presence.
Sally Jones, Director, Investor Relations and Corporate Communications
+44 20 7269 8407
David Allchurch, Tulchan Communications
+44 20 7353 4200